RARX Latest News, Press Relases and Analysis

All

Press Releases

5 years ago - By: Seeking Alpha - Mentions: APLS ALXN BCRX AKTX ...

Apellis on go to file U.S. application for pegcetacoplan for rare blood disorder (NASDAQ:APLS)

6 years ago - By: Zacks Investment Research

Is RA PHARMCTL INC (RARX) Stock Outpacing Its Medical Peers This Year?

6 years ago - By: Zacks Investment Research

How Ra Pharmaceuticals (RARX) Stock Stands Out in a Strong Industry

6 years ago - By: Benzinga - Mentions: OPK XBI ATHX HSIC ...

The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests

6 years ago - By: Benzinga - Mentions: ASTC USAU

Stocks That Hit 52-Week Highs On Wednesday

6 years ago - By: StockNews.com - Mentions: VIR GH EBS BJ ...

Best & Worst Performing Mid Cap Stocks for March 12, 2020

6 years ago - By: Analyst Ratings - Mentions: ARNA

Analysts Offer Insights on Healthcare Companies: Ra Pharmaceuticals (NASDAQ: RARX) and Arena Pharma (NASDAQ: ARNA)

6 years ago - By: Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals Supports 13th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases

6 years ago - By: Seeking Alpha

Ra Pharmaceuticals EPS misses by $0.16

6 years ago - By: Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

6 years ago - By: Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology

6 years ago - By: Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial

6 years ago - By: Zacks Investment Research - Mentions: ALKS INVA ANIK

Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug

6 years ago - By: Seeking Alpha

Ra Pharma commences mid-stage study of zilucoplan in rare type of myopathy

6 years ago - By: Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM

6 years ago - By: Halper Sadeh LLP - Mentions: IPHS FOMX

Merger Investigation Alert: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - IPHS, FOMX, RARX

6 years ago - By: Seeking Alpha

Ra Pharmaceuticals EPS misses by $0.05, beats on revenue

6 years ago - By: Ra Pharmaceuticals, Inc.

Ra Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

6 years ago - By: CNBC - Mentions: IBB AMGN CELG BIIB ...

Ra Pharmaceuticals Inc (RARX) Stock News

RARX Latest News, Press Relases and Analysis

Apellis on go to file U.S. application for pegcetacoplan for rare blood disorder (NASDAQ:APLS)

Is RA PHARMCTL INC (RARX) Stock Outpacing Its Medical Peers This Year?

How Ra Pharmaceuticals (RARX) Stock Stands Out in a Strong Industry

The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests

Stocks That Hit 52-Week Highs On Wednesday

Best & Worst Performing Mid Cap Stocks for March 12, 2020

Analysts Offer Insights on Healthcare Companies: Ra Pharmaceuticals (NASDAQ: RARX) and Arena Pharma (NASDAQ: ARNA)

Ra Pharmaceuticals Supports 13th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases

Ra Pharmaceuticals EPS misses by $0.16

Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology

Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial

Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug

Ra Pharma commences mid-stage study of zilucoplan in rare type of myopathy

Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM

Merger Investigation Alert: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - IPHS, FOMX, RARX

Ra Pharmaceuticals EPS misses by $0.05, beats on revenue

Ra Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Biotech stocks win October, rallying 8%